Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.59 USD | -1.68% | -12.00% | -23.61% |
Financials (USD)
Sales 2024 * | 189M | Sales 2025 * | 165M | Capitalization | 1.35B |
---|---|---|---|---|---|
Net income 2024 * | -325M | Net income 2025 * | -382M | EV / Sales 2024 * | 3.91 x |
Net cash position 2024 * | 610M | Net cash position 2025 * | 270M | EV / Sales 2025 * | 6.53 x |
P/E ratio 2024 * |
-3.86
x | P/E ratio 2025 * |
-3.47
x | Employees | 577 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 58.83% |
Latest transcript on Arcus Biosciences, Inc.
1 day | -1.68% | ||
1 week | -12.00% | ||
Current month | -22.72% | ||
1 month | -15.66% | ||
3 months | -4.89% | ||
6 months | -7.42% | ||
Current year | -23.61% |
Managers | Title | Age | Since |
---|---|---|---|
Juan Jaen
FOU | Founder | 66 | 14-12-31 |
Terry Rosen
CEO | Chief Executive Officer | 64 | 14-12-31 |
Robert Goeltz
DFI | Director of Finance/CFO | 51 | 20-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Terry Rosen
CEO | Chief Executive Officer | 64 | 14-12-31 |
Kathryn Falberg
BRD | Director/Board Member | 63 | 17-09-17 |
Yasunori Kaneko
BRD | Director/Board Member | 69 | 15-04-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.88% | 11 M€ | -6.03% | - | |
0.28% | 27 M€ | -5.75% | - | |
0.12% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 14.84 | 0.00% | 913,975 |
24-04-17 | 14.84 | -6.49% | 791,444 |
24-04-16 | 15.87 | -2.58% | 329,031 |
24-04-15 | 16.29 | -1.75% | 433,335 |
24-04-12 | 16.58 | -4.11% | 492,167 |
Delayed Quote Nyse, April 19, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.61% | 1.35B | |
-1.42% | 41.35B | |
+42.15% | 40.38B | |
+1.97% | 39.05B | |
-14.19% | 26.67B | |
+1.82% | 24.07B | |
-24.55% | 18.36B | |
-4.07% | 11.68B | |
+21.36% | 11.6B | |
+8.20% | 11.15B |
- Stock Market
- Equities
- RCUS Stock